phox430

PhOx430 is a first-in-class, orally administered small molecule inhibitor of N-acetylglucosaminyltransferase V (GnT-V), a key glycosylation enzyme involved in the synthesis of complex N-glycans. By selectively inhibiting GnT-V, PhOx430 disrupts aberrant glycosylation patterns on tumor cells, which are recognized as novel immune checkpoints that shield tumors from immune detection and promote cancer progression. This inhibition induces both an anti-cancer immune response and downregulation of membrane receptors implicated in tumor growth. Preclinical studies have demonstrated significant antitumoral efficacy and a promising safety profile. PhOx430 is being developed primarily for advanced or metastatic solid tumors, including glioblastoma multiforme and triple-negative breast cancer[1][2][3][5][6][7].

Other names

PhOx430PhOx-430PhOx 430